Steatohepatitis/Metabolic Liver Disease News

Increased liver fibrosis assessed by magnetic resonance elastography among patients with nonalcoholic fatty liver disease and type 2 diabetes correlated with a higher risk for cardiovascular risk, according to published data.

Results from a prospective study of patients with biopsy-proven nonalcoholic fatty liver disease showed that daily aspirin use correlated with less severe histologic features of fatty liver and nonalcoholic steatohepatitis and a lower risk for progression to advanced fibrosis.

Patients who followed a Mediterranean low-carbohydrate diet showed significant reductions in hepatic fat content beyond visceral adipose tissue changes that correlated with improvements in cardiometabolic parameters, according to a study published in Journal of Hepatology.

Promethera Biosciences dosed the first patient in a phase 2a clinical study of HepaStem for patients with late stage nonalcoholic steatohepatitis, according to a press release.

Due to significantly higher rates of steatosis and liver imaging, researchers linked intrahepatic cholestasis of pregnancy and nonalcoholic fatty liver disease.

3-V Biosciences dosed its first patient in a phase 2 clinical trial of a fatty acid inhibitor candidate from Ascletis for the treatment of nonalcoholic steatohepatitis, according to a press release.

Although the prevalence of alcoholic fatty liver disease among U.S. adults remained stable between 2001 and 2016, the prevalence of those with stage 2 or higher fibrosis increased significantly, according to a study published in JAMA.

Results from a survey presented at the third annual NASH Summit in Boston showed that awareness of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease remained low even among patients with the highest risk factors, according to a press release.

VIENNA — In this exclusive video from the International Liver Congress 2019, Harith Rajagopalan, MD, PhD, cofounder and CEO of Fractyl, discusses the use of the Revita duodenal mucosal resurfacing endoscopic technology for patients with concomitant type 2 diabetes and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.

This year at the International Liver Congress, researchers presented data on advances in clinical therapeutics for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis while also advocating for a focus on lifestyle intervention and needs for awareness.